Details of the Drug

General Information of Drug (ID: DMA8FS5)

Drug Name
Dronedarone
Synonyms
Multaq; Dronedarone [INN]; SR 33589; SR 33589B; Dronedarone (INN); Sanofi-Aventis brand of dronedarone; N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide; N-(2-Butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamide; N-[2-butyl-3-{4-[3-(dibutylamino)propoxy]benzoyl}-1-benzofuran-5-yl]methanesulfonamide; N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-methanesulfonamide
Indication
Disease Entry ICD 11 Status REF
Angina pectoris BA40 Approved [1], [2]
Atrial fibrillation BC81.3 Withdrawn from market [1], [3]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 3 Molecular Weight (mw) 556.8
Topological Polar Surface Area (xlogp) 7.2
Rotatable Bond Count (rotbonds) 18
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Clearance
The clearance of drug is 130-150 L/h [5]
Elimination
Following oral administration, about 84% of the labeled dose is excreted in feces and 6% is excreted in urine, mainly as metabolites [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 13 - 19 hours [5]
Metabolism
The drug is metabolized via the hepatic [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 20.5266 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.02% [7]
Vd
The volume of distribution (Vd) of drug is 1200-1400 L [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.5 mg/mL [4]
Chemical Identifiers
Formula
C31H44N2O5S
IUPAC Name
N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide
Canonical SMILES
CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC
InChI
InChI=1S/C31H44N2O5S/c1-5-8-12-29-30(27-23-25(32-39(4,35)36)15-18-28(27)38-29)31(34)24-13-16-26(17-14-24)37-22-11-21-33(19-9-6-2)20-10-7-3/h13-18,23,32H,5-12,19-22H2,1-4H3
InChIKey
ZQTNQVWKHCQYLQ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
208898
ChEBI ID
CHEBI:50659
CAS Number
141626-36-0
DrugBank ID
DB04855
TTD ID
D05CPV
VARIDT ID
DR00531
INTEDE ID
DR0550
ACDINA ID
D00218

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Potassium channel unspecific (KC) TT1VOHK NOUNIPROTAC Inhibitor [8]
Voltage-gated potassium channel Kv1.5 (KCNA5) TTW0CMT KCNA5_HUMAN Blocker [3]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [9]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [10]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Angina pectoris
ICD Disease Classification BA40
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 5.82E-01 -6.00E-02 -2.69E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 7.95E-01 -7.47E-02 -2.45E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 9.85E-01 2.24E-02 7.33E-02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Dronedarone
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Dronedarone and Ivabradine. Angina pectoris [BA40] [51]
Coadministration of a Drug Treating the Disease Different from Dronedarone (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Dronedarone and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [52]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Dronedarone and Midostaurin. Acute myeloid leukaemia [2A60] [53]
Gilteritinib DMWQ4MZ Major Increased risk of prolong QT interval by the combination of Dronedarone and Gilteritinib. Acute myeloid leukaemia [2A60] [53]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Dronedarone and Oliceridine. Acute pain [MG31] [53]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Dronedarone and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [53]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Dronedarone and Levalbuterol. Asthma [CA23] [54]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Dronedarone and Retigabine. Behcet disease [4A62] [53]
Cariprazine DMJYDVK Moderate Decreased metabolism of Dronedarone caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [55]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Dronedarone and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [56]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Dronedarone and Eribulin. Breast cancer [2C60-2C6Y] [53]
HKI-272 DM6QOVN Major Decreased metabolism of Dronedarone caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [57]
LY2835219 DM93VBZ Moderate Decreased metabolism of Dronedarone caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [58]
Tucatinib DMBESUA Major Decreased metabolism of Dronedarone caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [52]
Palbociclib DMD7L94 Moderate Decreased metabolism of Dronedarone caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [59]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Dronedarone caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [60]
Bosutinib DMTI8YE Major Decreased metabolism of Dronedarone caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [52]
Macitentan DMP79A1 Moderate Decreased metabolism of Dronedarone caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [61]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Dronedarone and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [53]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Dronedarone and Olodaterol. Chronic obstructive pulmonary disease [CA22] [62]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Dronedarone and Vilanterol. Chronic obstructive pulmonary disease [CA22] [54]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Dronedarone and Indacaterol. Chronic obstructive pulmonary disease [CA22] [62]
Fidaxomicin DMFP6MV Minor Decreased clearance of Dronedarone due to the transporter inhibition by Fidaxomicin. Clostridium difficile enterocolitis [1A04] [63]
Intedanib DMSTA36 Moderate Decreased metabolism of Dronedarone caused by Intedanib mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [64]
Ulipristal DMBNI20 Minor Decreased metabolism of Dronedarone caused by Ulipristal mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [65]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Dronedarone and Pasireotide. Cushing syndrome [5A70] [53]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Dronedarone and Osilodrostat. Cushing syndrome [5A70] [53]
Ivacaftor DMZC1HS Major Decreased metabolism of Dronedarone caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [65]
MK-8228 DMOB58Q Moderate Decreased metabolism of Dronedarone caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [66]
Rivaroxaban DMQMBZ1 Moderate Decreased metabolism of Dronedarone caused by Rivaroxaban mediated inhibition of CYP450 enzyme. Deep vein thrombosis [BD71] [52]
Vilazodone DM4LECQ Moderate Decreased metabolism of Dronedarone caused by Vilazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [67]
OPC-34712 DMHG57U Major Decreased metabolism of Dronedarone caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [68]
Polatuzumab vedotin DMF6Y0L Moderate Decreased metabolism of Dronedarone caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [69]
Alvimopan DMHR8KW Moderate Decreased clearance of Dronedarone due to the transporter inhibition by Alvimopan. Digestive system disease [DE2Z] [59]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Dronedarone and Ingrezza. Dystonic disorder [8A02] [53]
Cenobamate DMGOVHA Moderate Increased metabolism of Dronedarone caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [59]
Stiripentol DMMSDOY Moderate Decreased metabolism of Dronedarone caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [65]
Rufinamide DMWE60C Moderate Increased metabolism of Dronedarone caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [59]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Dronedarone caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [59]
Cannabidiol DM0659E Minor Decreased metabolism of Dronedarone caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [65]
Bay 80-6946 DMLOS5R Moderate Decreased metabolism of Dronedarone caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [70]
Tazemetostat DMWP1BH Major Decreased metabolism of Dronedarone caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [71]
Mirabegron DMS1GYT Minor Decreased metabolism of Dronedarone caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [72]
Ripretinib DM958QB Moderate Decreased metabolism of Dronedarone caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [52]
Avapritinib DMK2GZX Major Decreased metabolism of Dronedarone caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [65]
Levobetaxolol DMSREPX Moderate Increased risk of bradycardia by the combination of Dronedarone and Levobetaxolol. Glaucoma [9C61] [59]
Boceprevir DMBSHMF Major Decreased metabolism of Dronedarone caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [52]
Telaprevir DMMRV29 Major Decreased metabolism of Dronedarone caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [52]
Daclatasvir DMSFK9V Moderate Decreased metabolism of Dronedarone caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [52]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Dronedarone and Brentuximab vedotin. Hodgkin lymphoma [2B30] [73]
MK-1439 DM215WE Minor Decreased metabolism of Dronedarone caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [74]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Dronedarone and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [53]
Cobicistat DM6L4H2 Major Decreased metabolism of Dronedarone caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [52]
Dolutegravir DMCZGRE Minor Decreased metabolism of Dronedarone caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [75]
Etravirine DMGV8QU Moderate Increased metabolism of Dronedarone caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [59]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Dronedarone and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [53]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Dronedarone and Mipomersen. Hyper-lipoproteinaemia [5C80] [76]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Dronedarone and Teriflunomide. Hyper-lipoproteinaemia [5C80] [53]
BMS-201038 DMQTAGO Major Decreased metabolism of Dronedarone caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [52]
Aliskiren DM1BV7W Moderate Decreased metabolism of Dronedarone caused by Aliskiren mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [53]
Tolvaptan DMIWFRL Moderate Decreased metabolism of Dronedarone caused by Tolvaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [77]
Pirfenidone DM6VZFQ Moderate Decreased metabolism of Dronedarone caused by Pirfenidone mediated inhibition of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [65]
Berotralstat DMWA2DZ Major Decreased clearance of Dronedarone due to the transporter inhibition by Berotralstat. Innate/adaptive immunodeficiency [4A00] [78]
Suvorexant DM0E6S3 Major Decreased metabolism of Dronedarone caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [79]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Dronedarone caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [80]
ITI-007 DMUQ1DO Major Decreased metabolism of Dronedarone caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [81]
Polyethylene glycol DM4I1JP Major Increased risk of ventricular arrhythmias by the combination of Dronedarone and Polyethylene glycol. Irritable bowel syndrome [DD91] [82]
Naloxegol DML0B41 Major Decreased metabolism of Dronedarone caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [65]
Pemigatinib DM819JF Major Decreased metabolism of Dronedarone caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [65]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Dronedarone and Crizotinib. Lung cancer [2C25] [53]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Dronedarone caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [83]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Dronedarone and Osimertinib. Lung cancer [2C25] [53]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Dronedarone caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [84]
Capmatinib DMYCXKL Moderate Decreased metabolism of Dronedarone caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [85]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Dronedarone and Selpercatinib. Lung cancer [2C25] [53]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Dronedarone and Lumefantrine. Malaria [1F40-1F45] [53]
Artesunate DMR27C8 Moderate Decreased clearance of Dronedarone due to the transporter inhibition by Artesunate. Malaria [1F40-1F45] [59]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Dronedarone and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [53]
Idelalisib DM602WT Major Decreased metabolism of Dronedarone caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [52]
GDC-0199 DMH0QKA Major Decreased metabolism of Dronedarone caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [52]
IPI-145 DMWA24P Moderate Decreased metabolism of Dronedarone caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [59]
Acalabrutinib DM7GCVW Major Decreased metabolism of Dronedarone caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [86]
Ibrutinib DMHZCPO Major Decreased metabolism of Dronedarone caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [87]
Ponatinib DMYGJQO Moderate Decreased metabolism of Dronedarone caused by Ponatinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [88]
Arry-162 DM1P6FR Moderate Decreased clearance of Dronedarone due to the transporter inhibition by Arry-162. Melanoma [2C30] [52]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Dronedarone and Vemurafenib. Melanoma [2C30] [53]
Selumetinib DMC7W6R Major Decreased metabolism of Dronedarone caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [89]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Dronedarone caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [65]
Ubrogepant DM749I3 Moderate Decreased metabolism of Dronedarone caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [90]
Rimegepant DMHOAUG Moderate Decreased metabolism of Dronedarone caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [91]
Flibanserin DM70DTN Major Decreased metabolism of Dronedarone caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [92]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Dronedarone and Panobinostat. Multiple myeloma [2A83] [53]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Dronedarone and Siponimod. Multiple sclerosis [8A40] [52]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Dronedarone and Fingolimod. Multiple sclerosis [8A40] [53]
Ozanimod DMT6AM2 Major Increased risk of prolong QT interval by the combination of Dronedarone and Ozanimod. Multiple sclerosis [8A40] [53]
Deflazacort DMV0RNS Major Decreased metabolism of Dronedarone caused by Deflazacort mediated inhibition of CYP450 enzyme. Muscular dystrophy [8C70] [65]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Dronedarone and Romidepsin. Mycosis fungoides [2B01] [53]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Dronedarone caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [59]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Dronedarone and Nilotinib. Myeloproliferative neoplasm [2A20] [53]
Ruxolitinib DM7Q98D Minor Decreased metabolism of Dronedarone caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [65]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Dronedarone and Entrectinib. Non-small cell lung cancer [2C25] [53]
Lofexidine DM1WXA6 Major Increased risk of prolong QT interval by the combination of Dronedarone and Lofexidine. Opioid use disorder [6C43] [53]
S-297995 DM26IH8 Moderate Decreased metabolism of Dronedarone caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [65]
Olaparib DM8QB1D Major Decreased metabolism of Dronedarone caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [52]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Dronedarone and Rucaparib. Ovarian cancer [2C73] [53]
MK-4827 DMLYGH4 Moderate Decreased clearance of Dronedarone due to the transporter inhibition by MK-4827. Ovarian cancer [2C73] [93]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Dronedarone and Triclabendazole. Parasitic worm infestation [1F90] [53]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Dronedarone and Pimavanserin. Parkinsonism [8A00] [53]
Abametapir DM2RX0I Moderate Decreased metabolism of Dronedarone caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [94]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Dronedarone and Macimorelin. Pituitary gland disorder [5A60-5A61] [95]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Dronedarone and Lefamulin. Pneumonia [CA40] [53]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Dronedarone caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [52]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Dronedarone and Degarelix. Prostate cancer [2C82] [53]
ABIRATERONE DM8V75C Major Increased risk of prolong QT interval by the combination of Dronedarone and ABIRATERONE. Prostate cancer [2C82] [53]
Enzalutamide DMGL19D Major Increased risk of prolong QT interval by the combination of Dronedarone and Enzalutamide. Prostate cancer [2C82] [53]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Dronedarone and Relugolix. Prostate cancer [2C82] [53]
Darolutamide DMV7YFT Minor Decreased metabolism of Dronedarone caused by Darolutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [96]
Silodosin DMJSBT6 Moderate Decreased clearance of Dronedarone due to the transporter inhibition by Silodosin. Prostate hyperplasia [GA90] [97]
Ambrisentan DMD1QXW Moderate Decreased clearance of Dronedarone due to the transporter inhibition by Ambrisentan. Pulmonary hypertension [BB01] [59]
Axitinib DMGVH6N Moderate Decreased metabolism of Dronedarone caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [65]
Temsirolimus DMS104F Moderate Decreased metabolism of Dronedarone caused by Temsirolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [98]
Upadacitinib DM32B5U Moderate Decreased metabolism of Dronedarone caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [99]
Tofacitinib DMBS370 Moderate Decreased metabolism of Dronedarone caused by Tofacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [52]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Dronedarone and Iloperidone. Schizophrenia [6A20] [53]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Dronedarone and Amisulpride. Schizophrenia [6A20] [53]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Dronedarone and Asenapine. Schizophrenia [6A20] [53]
Avanafil DM75CXN Major Decreased metabolism of Dronedarone caused by Avanafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [100]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Dronedarone caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [59]
LDE225 DMM9F25 Major Decreased metabolism of Dronedarone caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [101]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Dronedarone caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [65]
Larotrectinib DM26CQR Moderate Decreased metabolism of Dronedarone caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [59]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Dronedarone and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [65]
Armodafinil DMGB035 Moderate Increased metabolism of Dronedarone caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [59]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Dronedarone and LEE011. Solid tumour/cancer [2A00-2F9Z] [53]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Dronedarone and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [53]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Dronedarone and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [53]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Dronedarone and Pitolisant. Somnolence [MG42] [53]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Dronedarone and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [53]
Pomalidomide DMTGBAX Moderate Decreased clearance of Dronedarone due to the transporter inhibition by Pomalidomide. Systemic sclerosis [4A42] [52]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Dronedarone due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [102]
Apixaban DM89JLN Moderate Decreased metabolism of Dronedarone caused by Apixaban mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [65]
Brilinta DMBR01X Moderate Decreased metabolism of Dronedarone caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [65]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Dronedarone and Lenvatinib. Thyroid cancer [2D10] [53]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Dronedarone and Cabozantinib. Thyroid cancer [2D10] [53]
Saxagliptin DMGXENV Moderate Decreased metabolism of Dronedarone caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [65]
Elagolix DMB2C0E Moderate Increased metabolism of Dronedarone caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [59]
Fluticasone DMGCSVF Moderate Decreased metabolism of Dronedarone caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [52]
⏷ Show the Full List of 146 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Crospovidone E00626 Not Available Disintegrant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Poloxamer 407 E00646 Not Available Emulsifying agent; Solubilizing agent; Surfactant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Hydrophobic colloidal silica E00285 24261 Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Pregelatinized starch E00674 Not Available Binding agent; Diluent; Disintegrant
⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Dronedarone Hydrochloride eq 400mg base tablet eq 400mg base Tablet Oral
Dronedarone 400 mg tablet 400 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7465).
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
4 BDDCS applied to over 900 drugs
5 FDA Approved Drug Products: Multaq (dronedarone) oral tablets
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
9 Drug safety evaluation of dronedarone in atrial fibrillation. Expert Opin Drug Saf. 2012 Nov;11(6):1023-45.
10 Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats. Eur J Pharm Sci. 2018 Jan 1;111:13-19.
11 Inactivation of human cytochrome P450 3A4 and 3A5 by dronedarone and N-desbutyl dronedarone. Mol Pharmacol. 2016 Jan;89(1):1-13.
12 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
22 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
23 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
24 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
25 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
26 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
27 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
28 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
29 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
30 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
31 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
32 Drug Interactions Flockhart Table
33 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
34 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
35 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
36 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
37 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
38 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035504)
39 Stereoselective effects of the enantiomers of a new local anaesthetic, IQB-9302, on a human cardiac potassium channel (Kv1.5). Br J Pharmacol. 2001 Jan;132(2):385-92.
40 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 542).
41 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
42 Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor. J Cardiovasc Pharmacol. 2013 May;61(5):408-15.
43 DOI: 10.1161/01.CIR.94.3.562
44 Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994 Jun;45(6):1227-34.
45 Substituted N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 ion channel blockers. Part 2. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6989-92.
46 Mechanism of clofilium block of the human Kv1.5 delayed rectifier potassium channel. Mol Pharmacol. 1995 Jan;47(1):198-205.
47 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
48 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
49 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
50 Azimilide. Drugs. 2000 Feb;59(2):271-7; discussion 278-9.
51 Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67. [PMID: 19667002]
52 Cerner Multum, Inc. "Australian Product Information.".
53 Canadian Pharmacists Association.
54 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
55 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
56 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
57 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
58 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
59 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
60 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
61 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
62 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
63 Product Information. Dificid (fidaxomicin). Optimer Pharmaceuticals, San Diego, CA.
64 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
65 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
66 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
67 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
68 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
69 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
70 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
71 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
72 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
73 Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
74 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
75 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
76 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
77 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
78 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
79 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
80 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
81 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
82 Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
83 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
84 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
85 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
86 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
87 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
88 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
89 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
90 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
91 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
92 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
93 Product Information. Zejula (niraparib). Tesaro Inc., Waltham, MA.
94 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
95 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
96 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
97 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
98 Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
99 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
100 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
101 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
102 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".